A phase I trial of alpha fetoprotein specific autologous genetically modified T-cells in patients with hepatocellular carcinoma

Trial Profile

A phase I trial of alpha fetoprotein specific autologous genetically modified T-cells in patients with hepatocellular carcinoma

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2016

At a glance

  • Drugs Cell therapies (Primary)
  • Indications Liver cancer
  • Focus Adverse reactions
  • Sponsors Adaptimmune
  • Most Recent Events

    • 08 Aug 2016 According to an Adaptimmune media release, the Investigative New Drug (IND) for this trial is open and the company anticipates initiation in the first half of 2017.
    • 25 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top